Xin and colleagues proposed that the hyperactivation of the oncogenic MAPK pathway in prostate cancer was partly due to PSGR1-induced activation of MAPKs ERK1/2 via a specific GA-localized Gβγ-PI3Kγ-ARF1 pathway (Xu et al., 2022). The gene discussed is MAPK3; the disease is prostate cancer.